Novel therapeutic approach to atrial fibrillation: AT1- receptorblocker;Innovativer therapieansatz bei vorhofflimmern: AT1- rezeptorblockade

Deutsche Medizinische Wochenschrift

Volumn 131, Issue 34-35 SUPPL., 2006, Pages

  Goette, Andreas ^a  

^a Orthopädische Universitälsklinik Otto Von Guericke   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; IRBESARTAN; LOSARTAN;

CARDIOVASCULAR RISK; CARDIOVERSION; DRUG MECHANISM; DRUG RESEARCH; HEART ATRIUM FIBRILLATION; HEART MUSCLE CONTRACTILITY; HUMAN; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SECONDARY PREVENTION;

EID: 33749583554     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-949185     Document Type: Review

References (26)

1. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med 2001; 250: 382-389
2. Tedesco MA, Di Salvo G, Ratti G, Natale F, Iarussi D, Iacono A. Left atrial size in 164 hypertensive patients: an echocardiographic and ambulatory blood pressure study. Clin Cardiol 2001; 24: 603-607
3. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998; 82: 2N-9N
4. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719
5. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-2931
6. Maggioni A, Latini R, Carson P et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-557
7. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86-92
8. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999; 100: 376-380
9. Healey JS, Baranchuk A, Crystal E et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839
10. Madrid AH, Bueno MC, Rebollo JM et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002; 106: 331-336
11. Ueng KC, Tsai TP, Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098
12. Dobrev D. Elektrisches Remodeling bei Vorhofflimmern. Herz 2006; 31:108-112
13. Gassanov N, Brandt MC, Michels G, Lindner M, Er F, Hoppe UC. Angiotensin II-induced changes of calcium sparks and ionic currents in human atrial myocytes: potential role for early remodeling in atrial fibrillation. Cell Calcium 2006; 39: 175-186
14. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617
15. Hove-Madsen L, Llach A, Bayes-Genis A et al. Atrial fibrillation is associated with increased spontaneous calcium release from the sarcoplasmic reticulum in human atrial myocytes. Circulation 2004; 110: 1358-1363
16. Goetre A, Lendeckel U, Klein HU. Signal transduction systems and atrial fibrillation. Cardiovasc Res 2002; 54: 247-258
17. Verdecchia P, Reboldi G, Gattobigio R et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003; 41: 218-223
18. Malmqvist K, Kahan T, Edner M, Bergfeldt L. Comparison of actions of irbesartan versus atenolol on cardiac repolarization in hypertensive left ventricular hypertrophy: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation Versus Atenolol (SILV-HIA). Am J Cardiol 2002; 90: 1107-1112
19. Bukowska A, Lendeckel U, Hirte D et al. Activation of the calcineurin signaling pathway induces atrial hypertrophy during atrial fibrillation. Cell Mol Life Sci 2006; 63: 333-342
20. Nitta T, Imura H, Bessho R, Hosaka H, Yamauchi S, Tanaka S. Wavelength and conduction inhomogeneity in each atrium in patients with isolated mitral valve disease and atrial fibrillation. J Cardiovasc Electrophysiol 1999; 10: 521-528
21. Kawara T, Derksen R, de Groot JR et al. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation 2001; 104: 3069-3075
22. Wolf PA, Dawber TR, Jr. Thomas HE, Kannel WB. Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology 1978; 28: 973-977
23. Wachtell K, Hornestam B, Lehto M et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 705-711
24. Wachtell K, Lehto M, Gerdts E et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719
25. Cai H, Li Z, Goette A et al. Downregulation of nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 2002; 106: 2854-2858
26. Hammwöhner M, Ittenson A, Dierkes J et al. Erhöhte thrombozytäre Expression von CD40/CD40L sowie systemischer und atrialer Adhäsionsmoleküle und MCP-1 bei persistierendem Vorhofflimmern. Clin Res Cardiol 2006; 95 (Suppl 5): 1278